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ABSTRACT 
 
Atrial fibrillation (AF) is one of the major cardiovascular diseases, and the number of 
patients with AF is predicted to increase markedly in the coming years. Despite recent 
advance in management of patients with AF, AF remains one of the main causes of 
stroke or systemic embolism. Application of simple stroke risk-stratification schemes, 
such as the CHA2DS2-VASc score has been introduced to identify patients who mostly 
benefit from oral anticoagulants (OACs) for stroke prevention. Current medical devices 
allow the detection of short and asymptomatic episodes of AF, termed atrial high rate 
episodes (AHREs), which are also associated with an increased risk of 
thromboembolism. Early diagnosis of AF has clinical importance for a timely initiation 
of OAC, while strokes often occur without AHRE detected within 30 days before the 
event. Consequently, it is unclear whether any AHRE imply the same therapeutic 
requirements as clinical AF. The exact estimation of AF burden and correct risk 
stratification in patients with asymptomatic AF and AHRE remains a challenge in clinical 
practice.  
 
 
Keywords 
Atrial fibrillation burden; Diagnosis; Clinical outcomes; Anticoagulation 
 
 
 
Alphabetical List of Abbreviations: 
AF = atrial fibrillation; AHRE = atrial high rate episode; CI = confidence interval; CIED = 
cardiac implantable electronic device; CRT = cardiac resynchronization therapy; ECG = 
electrocardiogram; HF = heart failure; HR = hazard ratio; ICD = implantable 
cardioverter-defibrillator; ILR = implantable loop recorder; NOAC = non-vitamin K 
antagonist oral anticoagulant; NSR = normal sinus rhythm; OAC = oral anticoagulant; 
VKA = vitamin K antagonist 
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Introduction 
Atrial fibrillation (AF) is globally the most common cardiac arrhythmia, with a 
prevalence of 2.5 to 3.2% of the population.1 Although the management of patients 
with AF has been increasing in the last decade, AF remains a major cause of stroke, 
heart failure (HF), sudden death, unplanned hospital admissions2, 3 and leads to an 
impaired quality of life.4 Thus, AF is associated with a 5-fold greater risk of ischemic 
stroke or systemic embolism compared with normal sinus rhythm.3, 5  
 
AF-related stroke is particularly more likely to be fatal or severely disabling.6 Thus, 
stroke prevention is the cornerstone of the management of patients with AF. 
 
Risk factors of stroke in patients with AF have been widely described7 and oral 
anticoagulation (OAC) is well established as effective stroke prevention. The Vitamin K 
antagonists (VKAs, e.g. warfarin) are still used in many countries as first choice OAC. 
Treatment with warfarin can reduce the risk of stroke by 60%-70%.8 More recently, the 
non-vitamin K antagonist oral anticoagulants (NOACs) have been approved and 
introduced in the market. The NOACs demonstrate relative efficacy, safety and 
convenience in comparison to warfarin in 4 phase-3 large randomized controlled 
trials,9-12 particularly with a significantly lower risk of intracranial haemorrhage, which 
is the most feared complication of OAC. Indeed, NOACs provide more convenient 
therapeutic options compared to warfarin and are increasingly adopted in clinical 
practice. 
 
Patients with AF may have a variety of symptoms with different levels of severity of 
palpitations, dyspnea, chest discomfort, and syncope. Among patients with AF, the 
prevalence of those having no or few symptoms related to AF, termed silent or 
asymptomatic AF, was reported to be up to 40% in one previous study.13 Even in the 
same patient, AF sometimes presents with symptoms, whereas some others may be 
asymptomatic.  
 
In clinical practice, AF is known to progress from short, infrequent and self-limiting 
episodes to longer and more sustained episodes. Current accepted definition of AF 
include 1) ‘Paroxysmal AF’ that spontaneously terminates in most cases within 48 
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hours, and lasts for up to 7 days; 2) ‘Persistent AF’ that is not self-terminating, and is 
sustained longer than 7 days, including episodes that are terminated by cardioversion, 
either with drugs or by direct current cardioversion or ablation after7 days or more; 3) 
‘ Permanent AF,’ previously referred to as ‘chronic AF’, is sustained longer than 1 year, 
and implicates a shared decision between physician and patient to adopt a rate control 
strategy with no further attempt to restore sinus rhythm. AF proceeds from paroxysmal 
into persistent, and eventually into permanent AF, with an annual rate reaching 15% at 
1 year.14 Some studies have suggested that permanent AF may be associated with a 
higher risk of stroke and mortality compared to paroxysmal AF15-17, but there is no 
general agreement on this aspect.18 Patients with silent or asymptomatic AF rarely 
undertake some medical examinations in clinical practice, and they are noticed 
incidentally through a wide variety of methods including routine physical examination, 
pre-operative assessments or population surveys. Some patients are sometimes first 
diagnosed with AF after presentation with severe complications such as ischemic 
stroke and HF. In >15% of patients presenting with cryptogenic stroke, underlying silent 
paroxysmal AF may be present.19 
  
Current medical devices using the latest technology can provide useful information to 
detect AF early and initiate medical intervention. However, silent or asymptomatic AF 
has not been sufficiently evaluated for its clinical impact. Therefore, the accurate 
evaluation of AF in ‘at risk’ populations should be explored. Early recognition of AF 
allows the clinicians to initiate the treatments for AF, leading to not only suppression of 
AF progression, but also prevention from AF-related complications.  
 
The purpose of this review is to provide an overview of 1) methods to detect the 
presence of silent or asymptomatic AF, 2) rates of ischemic stroke and 3) 
anticoagulation strategies in patients with AF.  
 
Detection of Silent or Asymptomatic AF 
Surface 12-lead electrocardiography (ECG) and 24-hour Holter ECG are golden standard 
tools recommended for the diagnosis of AF.20 However, silent or asymptomatic AF is 
unlikely to be detected by these ‘brief’ temporal ECG recordings. As a result, it is likely 
that AF would remain undiagnosed and undertreated with conventional methods. 
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Therefore, longer continuous ECG monitoring is needed for detection of silent or 
asymptomatic AF. The latest medical devices using novel technology have enabled us 
to monitor cardiac rhythm for long-term and to detect AF that was not diagnosed in 
routine clinical practice. Furthermore, recent studies indicate that quantifying the 
duration or burden of AF would lead to a basis for therapeutic indication for silent AF.21 
 
Cardiac implantable electronic devices (CIED) including pacemaker, and implantable 
cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) have been 
introduced for the management of symptomatic bradycardias and pauses, 
life-threatening tachyarrhythmias, and heart failure with reduced ejection fraction. In 
addition to their main functions, these devices are also capable of automatic long-term 
recording and storing of episodes of spontaneous atrial high rate episodes (AHREs).  
 
CIEDs with an atrial lead allow continuous monitoring of atrial rhythm and can record 
AHREs with the programmable detection criteria, which can be manually adjusted. 
Although mechanical problems such as lead-related noise, far-field oversensing, and 
some false positive recordings due to other tachyarrhythmias,22, 23 more recent CIEDs 
have well-programmed technologies, which can discriminate whether the high rate 
episodes are likely to be attributable to AF or not.  
 
For the detection of AHRE, previous studies adopted as cut-off settings for the atrial 
tachycardia, a rate between 170 and 225 bpm, with the duration of the episode of 
more than 20 seconds (Table 1).24-32 In these studies, the AHREs were detected in a 
variable range from 20% to 70% of patients with CIEDs (Table 1). In the Italian AT500 
registry, which included 725 patients with pacemaker indication for bradycardia and a 
history of atrial tachyarrhythmias, the AHREs lasting more than 5 minutes were found 
in 73.8% of the patients over a median 22-month follow-up.26 On the other hand, the 
ASSERT study, which included 2580 patients with CIEDs and no history of AF, 
demonstrated that the AHREs lasting more than 6 minutes were found in 34.7% of the 
patients over a mean follow-up of 2.5 years.29  
 
These different reported incidences of AHREs may be dependent on the underlying 
heart diseases and the period of follow-up. However, these results suggested that 
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there is a considerable number of patients with CIEDs who are incidentally diagnosed 
with AF.  
  
The implantable loop recorder (ILR), which is a subcutaneous, single-lead, ECG 
monitoring device, is used for AF detection in patients who have recurrent unexplained 
episodes of palpitation or syncope, and/or a history of cryptogenic stroke.33 This device 
usually recognizes AF by detecting the irregularity of successive R-R intervals. In 
particular, AF that is first diagnosed after cryptogenic stroke occurs is most often 
asymptomatic and paroxysmal, and is unlikely to be detected by strategies based on 
symptom-driven monitoring or short-term recordings.  
 
The ILR has been validated for more comprehensive arrhythmia monitoring in patients 
with cryptogenic stroke (Table 2).34-39 In the CRYSTAL-AF study, AF was more commonly 
detected in patients with ILR compared to those with conventional strategies (hazard 
ratio (HR), 7.3; 95% confidence interval (CI), 2.6 to 20.8; P<0.001).38 These studies 
indicate that ILR is beneficial for detection of silent or asymptomatic AF, but ILR devices 
are not always available and indications for ILR implantation require further 
standardization. On the other hand, the external ambulatory continuous ECG 
monitoring, such as a wearable non-adhesive dry-electrode belt and a wearable-patch 
has been introduced for AF detection in general population (Table 2).19, 40 Although the 
monitoring duration of these devices are shorter (2 to 4 weeks) compared to the 
implantable devices, these devices are less invasive and convenient than the 
implantable devices, and the feasibility for the detection of AF in general population 
has been verified in previous studies (Table 2). 
  
Furthermore, novel technologies have been developed and applied for the screening of 
AF. The new screening devices using blood pressure monitors and smartphone can 
detect AF based on pulse irregularity and specific algorithms with high sensitivity and 
specificity (Table 3).41-47 Patients can routinely and readily operate at home, whereas 
the utility for AF detection strongly depends on patients’ compliance. In the future, the 
acceptability, and cost-effectiveness of these methods must be explored in clinical 
practice. 
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Stroke in Patients with Silent or Asymptomatic AF 
Adverse stroke outcomes in relation to silent or asymptomatic AF have been reported 
in previous studies. In a community-based study, which enrolled 4,618 patients who 
were newly diagnosed with AF, 25% had no symptoms and were 3 times more likely to 
have had an ischemic stroke preceding their AF diagnosis. Another study demonstrated 
that 33.8% out of 467 patients had asymptomatic AF at the time of the first AF 
diagnosis, and asymptomatic AF was associated with an increased risk for 
cardiovascular (HR, 3.12; 95% CI, 1.50 - 6.45) and all-cause mortality (HR, 2.96; 95% CI, 
1.89 - 4.64) compared to those with typical AF symptoms even after adjustment for 
CHA2DS2-VASc score and age.
48 
  
Previous studies regarding AHRE detected in patients with CIEDs have suggested that 
AHRE is associated with an increased stroke rate (Table 4). In the ASSERT study, for 
example, the presence of AHRE was associated with an increased risk of ischemic 
stroke or systemic embolism (HR 2.49; 95% CI 1.28 - 4.85; P = 0.007). However, the risk 
of stroke seems to be lower in patients with AHREs than those with clinically 
ECG-detected AF and similar CHADS2 or CHA2DS2-VASc scores and probably depends on 
the fact that patients with CIEDs often have already been on medical treatment or 
support before AF-related complications occurred, thus reducing the incidence of 
thromboembolism.  
 
Moreover, the threshold time used to define AHREs was different in previous studies, 
providing variable rates of ischemic stroke. In the TRENDS study, which included 2486 
patients with ≧1 stroke risk factor, adjusted HRs were 0.98 (95% CI, 0.34- 2.82; P = 
0.97) in patents with AHREs <5.5 hours, and 2.20 (95% CI, 0.96- 5.05; P = 0.06) with 
AHREs ≧5.5 hours, compared to those without AHREs.27 On the other hand, the recent 
subanalysis of the ASSERT study, suggested that adjusted HRs were 0.75 (95% CI, 0.29- 
1.96; P = 0.56) in patents with AHREs >6 minutes to 6 hours, 1.32 (95% CI, 0.40- 4.37; P 
= 0.65) with AHREs >6 to 24 hours, and 3.24 (95% CI, 1.51 – 6.95; P = 0.003) AHREs >24 
hours, compared to those without AHREs.49 Therefore, the threshold to define AHRE 
remains uncertain, and randomized control trials are needed for quantifying duration 
time of AHRE that is associated with an increased thromboembolic risk. 
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Anticoagulation for Silent AF 
Anticoagulant therapy has been an established treatment for reducing stroke, systemic 
embolism, and all-cause mortality in patients with AF.50 However, inadequate 
therapeutic anticoagulation preceding stroke is prevalent in patients with AF even in 
specialized clinics for anticoagulation, where at least one third of patients had 
suboptimal anticoagulation control.51 Frequently patients without symptoms, 
especially those in normal sinus rhythm (NSR), may stop anticoagulation over time52; 
this is relevant as the cessation of OAC is independently associated with an increased 
risk of stroke, adverse cardiovascular events and mortality.53, 54 However, this issue 
seems to be partially overcome by the increasing use of NOACs55 
 
In a previous study, among patients admitted with acute ischemic stroke who had a 
history of AF, 83.6% of 94,474 patients were not receiving therapeutic anticoagulation; 
13.5% had subtherapeutic warfarin anticoagulation (INR <2) at stroke, 39.9% were 
receiving antiplatelet therapy only, and 30.3% were receiving no anticoagulant therapy. 
Moreover, patients with therapeutic anticoagulation had lower odds of moderate or 
severe stroke (NIHSS score 16) than those without therapeutic anticoagulation.56 In a 
cohort study of 5,555 patients without symptoms who were diagnosed with AF 
incidentally in general practice, the adjusted stroke and mortality rates at 1.5 years in 
patients receiving anticoagulant therapy were lower than in those receiving no 
anticoagulant therapy (1.3% vs. 3.9%, 4.2% vs. 7.2%, respectively).57 One recent 
multicentre study including 59 patients with a history of non-permanent AF and ILRs 
indicated that intermittent NOAC administration based on the presence of AF lasting 
more than 24 hours is feasible.58 
 
Although these results suggest that anticoagulant therapy may be beneficial in patients 
with silent AF as well as clinically ECG-detected AF, a randomized control trial 
demonstrated that anticoagulant therapy based on remote rhythm monitoring in 
patients with CIEDs did not show the improvement of thromboembolism compared to 
usual office-based follow-up (HR 1.06; 95% CI 0.75 - 1.51; P = 0.732).32 Investigators of 
this study showed that the main limitation of this strategy is the poor compliance with 
OAC in patients with remote rhythm monitoring follow-up. In addition, it remains 
unclear whether AHREs detected in patients with CIEDs imply the same therapeutic 
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requirements as clinically ECG-detected AF. 
 
Future Prospective 
Continuous long-term ECG monitoring and the new modalities of non-invasive ECG 
recording seem to be effective for the detection of silent or asymptomatic AF, however, 
there is still room for improvement on the utility, adherence, and cost-effectiveness for 
screening of silent AF in general population. Randomized control trials with larger 
sample size must be conducted to test the associations between ECG-detected silent 
AF and adverse outcomes. 
 
The major studies regarding silent or asymptomatic AF performed thus far are not 
comparable as they included inhomogeneous populations, such as patients with and 
without a history of prior AF at baseline. Furthermore, there was a lack of 
characterization/definition of clinical endpoints such as for ischemic stroke, i.e. 
cardioembolic, atherothrombotic, or lacunar infarction. Therefore, the association 
between newly detected silent AF and clinical outcomes should be further investigated. 
 
Although CIEDs-detected AHRE was shown to be significantly associated with an 
increased risk of thromboembolic events, the temporal relationship between AHREs 
and thromboembolic events remains uncertain. In previous studies, the majority of 
patients with AHRE detected by implantable devices, who experienced an ischemic 
stroke or systemic embolism, did not have any AT/AF or subclinical AF in the 30 days 
prior to the event, questioning the causal relationship between AHRE and 
thromboembolism.59, 60 Patients with AHREs may have transient blood stasis due to low 
flow in left atrial appendage and changes in atrial endothelium, leading to increased 
risk of thromboembolism. Consequently, the criteria of AHREs requiring medical 
intervention and the stratified stroke risk factors in patients with CIEDs must be fully 
explored.  
 
What trials will inform clinical practice? The ARTESiA (Apixaban for the Reduction of 
Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; 
NCT01938248) and NOAH (Non-vitamin K Antagonist Oral Anticoagulants in Patients 
With Atrial High Rate Episodes; NCT02618577) trials are ongoing studies on the benefit 
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of NOAC in patients with CIEDs, and will provide useful information on quantifying 
duration time of AHREs. 
 
 
Conclusions 
 
Silent or asymptomatic AF is still an under-recognized disease in the general population 
and is detectable in 25-35% of patients presenting with ischemic stroke. The use of 
diagnostic devices lead to a more accurate and early detection of AF, allowing a prompt 
initiation of OAC before the occurrence of severe and disabling events. CIEDs-detected 
AHREs were shown to be associated with an increased risk of stroke and frequently 
precede clinically overt AF.  
AHREs may represent an additional risk factor for stroke in patients with paroxysmal AF 
and sinus rhythm. Thus, these patients could benefit from an early initiation of OAC 
when AHREs are identified.61 However, there is still uncertainty and evidence gap in the 
management of patients with silent AF and AHREs, such as the number and /or length 
of AHREs to be considered as clinically relevant to start OAC. Appropriate management 
algorithms to estimate AF burden in the general population and to stratify the risk of 
thromboembolism should be further developed. 
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Table 1. Summary of the definition and incidence of AHRE in patients with CIEDs. 
 
Year Study 
Atrial detection 
rate 
Detection 
time 
Incidence of AHRE 
2002 Gillis AM, et al
23
 >180 bpm >1 minutes 157/231 (68%) 
2003 MOST
24
 >220 bpm >5 minutes 156/312 (50%) 
2005 Italian AT500 Registry
25
 >170 bpm n/a 524/725 (73.8%) 
2009 TRENDS
26
 >175 bpm >20 seconds 1389/2486 (55.9%) 
2012 Shanmugam N, et al
27
 >180 bpm >14 minutes 223/560 (39.8%) 
2012 ASSERT
28
 >190 bpm >6 minutes 895/2580 (34.7%) 
2014 Gonzalez M, et al
29
 >178 bpm >5 minutes 39/224 (17.4%) 
2015 Benezet-Mazuecos J, et al
30
 >225 bpm >5 minutes 28/109 (25.7%)  
2015 IMPACT
31
 >200 bpm n/a 945/2718 (34.8%) 
 
AHRE, atrial high rate episode; MOST, Mode Selection Trial; TRENDS, The Relationship 
Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and 
Stroke; ASSERT, Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker 
Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial; IMPACT, Randomized 
trial of atrial arrhythmia monitoring to guide anticoagulation in patients with 
implanted defibrillator and cardiac resynchronization devices.  
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Table 2. Summary of the implantable and external devices for the detection of AF. 
 
Year Study 
Detection 
time 
Follow-up period Incidence of AF 
Implantable ECG monitoring 
2013 Cotter PE, et al
33
 2 minutes 229 days (mean) 13/51 (25.5 %) 
2013 Ritter MA, et al
34
 2 minutes 382 days (median) 10/60 (16.7 %) 
2013 Etgen T, et al
35
 6 minutes 1 year 6/22 (27.3 %) 
2014 SURPRISE
36
 2 minutes 569 days (mean) 14/85 (16.1 %) 
2014 CRYSTAL-AF
37
 30 seconds >6 months 29/221 (12.4 %, 12 months) 
2016 Poli S, et al
38
 2 minutes >6 months 25/75 (33.3 %, 12 months)  
External ECG monitoring 
2014 EMBRACE
39
 30 seconds 30 days 45/280 (16.1%) 
2015 STUDY-AF
40
 30 seconds 14 days 4/75 (5.3%) 
 
SURPRISE, Stroke Prior to Diagnosis of Atrial Fibrillation using Longterm Observation 
with Implantable Cardiac Monitoring Apparatus Reveal; CRYSTAL-AF, Cryptogenic 
Stroke and Underlying Atrial Fibrillation; EMBRACE, Atrial Fibrillation in Patients with 
Cryptogenic Stroke; STUDY-AF, The Screening Study for Undiagnosed Atrial Fibrillation. 
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Table 3. Summary of the new devices for AF screening. 
 
Year Study Device Sensitivity (%) Specificity (%) 
2009 Doliwa PS, et al
41
 Handheld single-lead ECG 92 96 
2009 Samol A, et al
42
 Handheld single-lead ECG 100 100 
2012 Marazzi G, et al
43
 Blood pressure monitor 92 95 
2013 Wiesel J et al
44
 Blood pressure monitor 97 90 
2014 Kearly K, et al
45
 Blood pressure monitor 95 90 
2011 Lewis M, et al
46
 Plethysmograph 100 92 
2016 McManus DD, et al
47
 Plethysmograph 97 94 
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Table 4. Summary of thromboembolic rate in patients with CIEDs. 
 
Year Study 
Follow-up 
period 
Cut-off burden 
of AHREs 
Annualized TE 
rate (95% CI) 
Hazard ratio (95% CI) 
2003 MOST
24
 27 months 
<5min 0.58%  
>5min 2.22% 6.7 (P=0.02) 
2005 
Italian AT500 
Registry
25
 
22 months 
<5min 0.9%  
>5min 0.2%  
>24 h 1.8% 3.1 (1.1-10.5; P=0.04) 
2009 TRENDS
26
 1.4 years 
None 1.1% (0.8-1.6)  
<5.5 h 1.1% (0.4-2.8) 0.98 (0.34-2.82; P=0.97) 
>5.5 h 2.4% (1.2-4.5) 2.2 (0.96-5.05; P=0.06) 
2012 
Shanmugam 
N, et al
27
 
370 days 
<14min 
2% (overall) 
 
>14min-3.8h 4.3(0.73-26.2; P=0.11) 
>3.8 h 9.4 (1.8-47.0; P=0.01) 
2012 ASSERT
28
 2.5 years 
<6min 0.69%  
>6 min 1.69% 2.49 (1.28-4.89; P=0.01) 
2017 
Van Gelder IC, 
et al
50
 
2.5 years 
<6min 
n/a 
 
>6 min-6 h 0.75 (0.29–1.96; P=0.56)  
>6 h-24 h 1.32 (0.40–4.37; P=0.65)  
>24 h 3.24 (1.51–6.95; P<0.01) 
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